The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Epidermal growth factor-mediated signaling in ovarian cancer and the role of miR-34a and 6p22 gene amplification-based E2F3a control.
D. Reimer
No relevant relationships to disclose
H. Kiefel
No relevant relationships to disclose
M. Hubalek
No relevant relationships to disclose
M. Erdel
No relevant relationships to disclose
N. Concin
No relevant relationships to disclose
G. Hofstetter
No relevant relationships to disclose
E. Mueller-Holzner
No relevant relationships to disclose
P. Altevogt
No relevant relationships to disclose
C. Marth
No relevant relationships to disclose
A. G. Zeimet
No relevant relationships to disclose